A Phase 1 interventional study of Denosumab and Percutaneous core needle breast biopsy in Healthy Volunteer, Female, Breast, sponsored by Amgen. Completed at 3 sites in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-24.
Sponsored by Amgen · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate whether administration of denosumab results in a decrease compared to the control group in proliferation of mammary epithelial cells as measured by the Ki-67 proliferation index.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received no treatment and underwent percutaneous core needle breast biopsies on Day 1 and Day 28.
Procedure: Percutaneous core needle breast biopsy
Participants received 60 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.
Drug: Denosumab · Procedure: Percutaneous core needle breast biopsy
Participants received 120 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.
Drug: Denosumab · Procedure: Percutaneous core needle breast biopsy
Single sucutaneous dose
Log Ratio of Post-baseline to Baseline Ki-67 Index in Mammary Epithelial Cells
Ki-67 is a marker for cell proliferation. Participants underwent percutaneous core needle breast biopsies on Day 1 (Baseline, prior to treatment) and Day 28. Levels of Ki67 were measured using immunohistochemical staining and digital imaging. The proliferation index was calculated as the percentage of Ki-67 positive terminal ductal lobular unit (TDLU) and duct epithelial cells. The higher the percentage, the higher the rate of epithelial cell proliferation.
Time frame: Baseline and Day 28
| Milestone | No Treatment | Denosumab 60 mg | Denosumab 120 mg |
|---|---|---|---|
| Started | 27 | 27 | 28 |
| Completed | 27 | 27 | 28 |
| Not completed | 0 | 0 | 0 |
Ki-67 is a marker for cell proliferation. Participants underwent percutaneous core needle breast biopsies on Day 1 (Baseline, prior to treatment) and Day 28. Levels of Ki67 were measured using immunohistochemical staining and digital imaging. The proliferation index was calculated as the percentage of Ki-67 positive terminal ductal lobular unit (TDLU) and duct epithelial cells. The higher the percentage, the higher the rate of epithelial cell proliferation.
| log ratio | No Treatment | Denosumab 60 mg | Denosumab 120 mg |
|---|---|---|---|
| Log Ratio of Post-baseline to Baseline Ki-67 Index in Mammary Epithelial Cells | 0.084 ± 0.645 | -0.100 ± 1.048 | -0.081 ± 0.918 |
Collected over 28 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A No Treatment | — | 0/27 (0%) | 4/27 (14.8%) |
| Treatment B 60 MG SC | — | 0/27 (0%) | 6/27 (22.2%) |
| Treatment C 120 MG SC | — | 0/28 (0%) | 11/28 (39.3%) |
| Event | Treatment A No Treatment | Treatment B 60 MG SC | Treatment C 120 MG SC |
|---|---|---|---|
| Injection site erythemaGeneral disorders | 0/27 | 1/27 | 10/28 |
| Procedural painInjury, poisoning and procedural complications | 4/27 | 4/27 | 2/28 |
| Breast haematomaReproductive system and breast disorders | 0/27 | 2/27 | 0/28 |
| HeadacheNervous system disorders | 0/27 | 0/27 | 2/28 |
| Age, Continuous(years) | No Treatment | Denosumab 60 mg | Denosumab 120 mg | Total |
|---|---|---|---|---|
| Mean | 29.9 ± 7.3 | 32.2 ± 7.6 | 32.8 ± 8.8 | 32.5 ± 8.2 |
| Sex: Female, Male(Participants) | No Treatment | Denosumab 60 mg | Denosumab 120 mg | Total |
|---|---|---|---|---|
| Female | 27 | 27 | 28 | 82 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | No Treatment | Denosumab 60 mg | Denosumab 120 mg | Total |
|---|---|---|---|---|
| Asian | 0 | 0 | 1 | 1 |
| Black (or African American) | 4 | 8 | 10 | 22 |
| Multiple | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 2 |
| Whte | 21 | 19 | 16 | 56 |
The record gives a start of Apr 2014, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab